demonstrated suggested inconclusive safety concern ongoing study display ongoing demontrated benefit only
COVID-19 severe or critically
COVID 19 outpatients
antiviral and associated therapy
azithromycin Hinks ... PRINCIPLE ACTION
chloroquine and derivatives ALBERTA HOPE-Covid19
hydroxychloroquine COVID-PEP Severity ... BCN PEP-CoV-2-Study 2 ... Reis ... PATCH Cohort 1 ... COPE – Coalition V
fluvoxamine COVID-OUT ... TOGETHER ACTIV-6 Lenze ...
hydroxychloroquine plus macrolides
azithromycin plus hydroxychloroquine Q-PROTECT ... Rodrigues
ivermectin ACTIV-6 ... Chaccour TOGETHER ... Buonfrate ... IVERCORCOVID19 ... Lopez-Medina ACTIV 6 ivermectin COVID-OUT ...
lopinavir/ritonavir Reis ...
molnupiravir Fischer ... MOVe-OUT
nirmatrelvir / ritonavir (Paxlovid) EPIC-HR
remdesivir PINETREE ...
sofosbuvir and daclatasvir Roozbeh

10 studies excluded by filtering options 0

6031 NCT04621461, 0 000selection pending
6321 Podder, 2020 113high risk of bias
6381 Espitia-Hernandez, 2020 1310not a RCTrisk of bias not avaialble
6381 Espitia-Hernandez, 2020 1310not a RCTrisk of bias not avaialble
6607 Thomas (zinc only), 2021 110risk of bias not avaialble
6625 Nasir, 2020 2310excludednot a RCTrisk of bias not avaialble
6939 RM08-3008 (Rossignol), 2021 110risk of bias not avaialble
7314 Samaha, 2021 213excludedhigh risk of bias
8283 Chahla, 2021 133high risk of bias
9122 Ramachandran, 2021 010selection pending